A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 2, 2011, Pages 255-261

  Vickers, Andrew J ^a   Gupta, Amit ^a   Savage, Caroline J ^a   Pettersson, Kim ^b   Dahlin, Anders ^c   Bjartell, Anders ^c   Manjer, Jonas ^c   Scardino, Peter T ^a   Ulmert, David ^a,c   Lilja, Hans ^a,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF TURKU   (Finland)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN; PROSTATE SPECIFIC ANTIGEN;

ACCURACY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; COHORT ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; SWEDEN;

AGED; BIOPSY; COHORT STUDIES; EARLY DETECTION OF CANCER; FOLLOW-UP STUDIES; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL RATE;

EID: 79951626849     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-1003     Document Type: Article

References (20)

1. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008;8:268-78. (Pubitemid 351430866)
2. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
3. Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-9.
4. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725-32.
5. Crawford ED, Grubb R III, Black A, Andriole GL Jr, Chen MH, Izmirlian G, et al. Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol 2010.
6. Holmstrom B, Johansson M, Bergh A, Stenman UH, Hallmans G, Stattin P. Prostate specific antigen for early detection of prostate cancer: longitudinal study. BMJ 2009;339:b3537.
7. Vickers AJ, Cronin AM, Aus G, Pihl CG, Becker C, Pettersson K, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden. BMC Med 2008;6:19.
8. Steuber T, Vickers A, Haese A, Kattan MW, Eastham JA, Scardino PT, et al. Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. Int J Cancer 2007;120:1499-504. (Pubitemid 46355384)
9. Steuber T, Vickers AJ, Serio AM, Vaisanen V, Haese A, Pettersson K, et al. Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer. Clin Chem 2007;53:233-40. (Pubitemid 46338267)
10. Christensson A, Bjork T, Nilsson O, Dahlen U, Matikainen MT, Cockett AT, et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100-5. (Pubitemid 23175981)
11. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274:1214-20.
12. Vickers A, Cronin A, Roobol M. Reducing unnecessary biopsy during prostate cancer screening using a four kallikrein panel: an independent replication. J Clin Oncol 2010;28:2493-8.
13. Vickers AJ, Cronin AM, Roobol MJ, Savage CJ, Peltola M, Pettersson K, et al. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin Cancer Res 2010;16:3232-9.
14. Gupta A, Roobol MJ, Savage CJ, Peltola M, Pettersson K, Scardino PT, et al. A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands. Br J Cancer 2010;103:708-14.
15. Manjer J, Carlsson S, Elmstahl S, Gullberg B, Janzon L, Lindstrom M, et al. The Malmo Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants. Eur J Cancer Prev 2001;10:489-99. (Pubitemid 34048904)
16. Lilja H, Ulmert D, Bjork T, Becker C, Serio AM, Nilsson JA, et al. Longterm prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol 2007;25:431-6. (Pubitemid 350002992)
17. Ulmert D, Becker C, Nilsson JA, Piironen T, Bjork T, Hugosson J, et al. Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C. Clin Chem 2006;52:235-9. (Pubitemid 43185484)
18. Mitrunen K, Pettersson K, Piironen T, Bjork T, Lilja H, Lovgren T. Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem 1995;41:1115-20.
19. Vaisanen V, Peltola MT, Lilja H, Nurmi M, Pettersson K. Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments. Anal Chem 2006;78:7809-15.
20. Schröder FH, Bangma CH, Roobol MJ. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC. Eur Urol 2008;53:901-8.